Blockchain Registration Transaction Record

Onassis Launches $75M Reg A+ Funding for Longevity Breakthroughs

Onassis Holdings launches $75M Regulation A+ funding round for epigenetic rejuvenation technology through Dalmore Group, offering public investment in longevity biotech breakthroughs.

This development matters because it democratizes investment access to cutting-edge longevity biotechnology that could fundamentally transform healthcare and human lifespan. Onassis Holdings' epigenetic reprogramming technology represents a frontier in anti-aging science, potentially addressing age-related diseases that affect millions worldwide. The Regulation A+ offering allows everyday investors to participate in a sector typically reserved for venture capital and institutional money, while the company's research into cellular rejuvenation could lead to breakthrough therapies for conditions like Alzheimer's, cardiovascular disease, and other age-related disorders. As global populations age, advancements in longevity technology become increasingly critical for healthcare systems and quality of life.